You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CC-486 (ORAL AZACITIDINE)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematologic Tumor, Tumors Trial in Gainesville, Baltimore, Houston (CC-486)

Active, not recruiting
  • Hematologic Neoplasm
  • Neoplasms
  • Gainesville, Florida
  • +2 more
Jan 12, 2023

Hepatic Insufficiency, Tumors Trial in Port Jefferson Station, Cleveland (Onureg, Vidaza)

Not yet recruiting
  • Hepatic Insufficiency
  • Neoplasms
  • Port Jefferson Station, New York
  • +1 more
Jan 13, 2022

Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma Trial in Tampa (CC-486, Duvelisib)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 18, 2023

Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (Azacitidine, Pembrolizumab)

Active, not recruiting
  • Melanoma and Other Malignant Neoplasms of Skin
  • Metastatic Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 31, 2022

Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP

Active, not recruiting
Has Results
  • Previously Untreated Peripheral T-cell Lymphoma
  • CC-486 Administration
  • CHOP Administration
  • Tampa, Florida
  • +3 more
Jan 18, 2023

Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)

Not yet recruiting
  • Untreated Myelodysplastic Syndrome
  • Onureg + Venetoclax
  • Angers, France
  • +9 more
Mar 13, 2023

NSCLC Trial in Worldwide (CC-486, Pembrolizumab, Placebo)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • Glendale, Arizona
  • +33 more
Jan 12, 2023

Leukemia, Myeloid, Acute Trial in China (CC-486, Placebo)

Recruiting
  • Leukemia, Myeloid, Acute
  • Hefei, Anhui, China
  • +31 more
Jan 10, 2023

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial in Duarte (Nivolumab, Oral Azacitidine)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Nivolumab
  • Oral Azacitidine
  • Duarte, California
    City of Hope Medical Center
Feb 28, 2022

T-Cell Large Granular Lymphocyte Leukemia Trial in Columbus (Oral Azacitidine)

Recruiting
  • T-Cell Large Granular Lymphocyte Leukemia
  • Oral Azacitidine
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 18, 2022

MDS, CMML Trial in Florence (CC-486)

Recruiting
  • MDS
  • CMML
  • Florence, Italy
    AOU Careggi- University of Florence
Mar 16, 2021

MDS, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Australia (Azacitidine, CC-486)

Active, not recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Newcastle, New South Wales, Australia
  • +10 more
Mar 29, 2022

Colorectal Cancer Trial in Baltimore (Oral CC-486, Romidepsin, MK-3475)

Completed
  • Colorectal Cancer
  • Oral CC-486
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 21, 2022

MDS Trial in Worldwide (Oral Azacitidine, Durvalumab)

Active, not recruiting
Has Results
  • Myelodysplastic Syndromes
  • New Haven, Connecticut
  • +65 more
Aug 19, 2022

AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

Not yet recruiting
  • AML, Adult
  • +4 more
  • Amiens, France
  • +19 more
Sep 1, 2023

Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,

Active, not recruiting
  • Relapsed Angioimmunoblastic T-Cell Lymphoma
  • Refractory Angioimmunoblastic T-cell Lymphoma
  • Oral azacitidine
  • +3 more
  • Graz, Austria
  • +33 more
Aug 24, 2022

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Acute Myeloid Leukemia, Myelodysplasia Trial in United Kingdom (Oral azacitidine, Matched )

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplasia
  • Oral azacitidine
  • Matched placebo
  • Birmingham, United Kingdom
  • +20 more
Oct 14, 2021

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor Positive and

Completed
  • Microsatellite Stable Colorectal Carcinoma
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Mar 30, 2021

Acute Myeloid Leukemia Trial in Japan (Oral Azacitidine, Placebo)

Recruiting
  • Acute Myeloid Leukemia
  • Oral Azacitidine
  • Placebo
  • Nagoya, Aichi, Japan
  • +30 more
May 25, 2022

Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States

Recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • +6 more
  • Los Angeles, California
  • +20 more
Aug 2, 2022

Acute Myelogenous Leukemia (AML) Trial in Summit (CC-486)

Approved for marketing
  • Acute Myelogenous Leukemia (AML)
  • Summit, New Jersey
    Celgene
Sep 16, 2020

Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)

Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

Suspended
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • +20 more
  • Tucson, Arizona
  • +110 more
Jan 31, 2023